Eyes on VRTXVRTX bouncing nicely off recent lows and has broken downtrend. Final confirmation would be a daily close over 421.50. Looking to enter a starter position and will add on a retest of the daily 48.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
14.45EUR
3.28 BEUR
8.91 BEUR
257.43 M
About Vertex Pharmaceuticals Incorporated
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Employees (FY)
5.4 K
Founded
1989
FIGI
BBG00GQ6SBQ9
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated
In waiting for a retestAre you interrested in buying NASDAQ:VRTX ? I'm looking for a break confirmation of the 2-years trendline to evaluate a first entry in the 370s. Then the POC line could be a valid support to regain the trend.
VRTX Stock – the Alternative to OxyContin?In the wake of the opiod epidemic, brought on in part by the success of Oxycodone, a new exceptional drug is being developed by Vertex Pharmaceuticals (NASDAQ: VRTX). With the intention of providing relief from severe pain without the addictive properties of opioids, Vertex’s new drug could be on tr
temporary pain for long term gainsAs price action is currently receiving short term bearishness from sellers from being near all time highs, accumulation of shares are lessening however the uptrend has been strong overall. Look for more of a pullback leading into earnings and with strong support should provide another entry long in
Stock of the Month: Vertex (VRTX)Our portfolio is up by more than 15% in the month of November. We are strictly following Mark Minervini's Trading Methodology. Here is a quick summary:
Mark Minervini's trading methodology, often encapsulated in his SEPA (Specific Entry Point Analysis) system, is a comprehensive approach to trading
Vertex’s Stock Heads for All-Time HighVertex Pharmaceuticals Inc. shares were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
The stock jumped more than 10% Wednesday morning, on pace for its largest percentage gain in more than three years, and w
Vertex Pharmaceuticals: Riding the Bullish Wave with a Bull Put In the world of trading, there are a variety of strategies that investors can employ to maximize their returns. One such strategy that has gained popularity in recent years is the vertical spread bull put. This strategy involves buying a put option with a lower strike price and selling a put option
VRTX shortHi traders,
let's have a look at VRTX analysis on daily timeframe.
The support at 342$ has been retested many times however, this time we are expecting support to fail.
If horizontal support fails and the price breaks upslopping support (blue line), it will look more bearish and short position ca
Trading Idea: Buy Vertex Pharmaceuticals (VRTX) StockVertex Pharmaceuticals (VRTX) has experienced a decline of around 5.84% in its share price over the past month. However, based on the provided facts, it appears that Vertex Pharmaceuticals is in a strong financial position and could be a good investment opportunity.
Here is the core logic behind th
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where VRTX is featured.
Frequently Asked Questions
The current price of VRTX is 390.85 EUR — it has increased by 1.10% in the past 24 hours. Watch VERTEX PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange VERTEX PHARMACEUTICALS INC stocks are traded under the ticker VRTX.
VERTEX PHARMACEUTICALS INC is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
VRTX stock is 1.09% volatile and has beta coefficient of 0.88. Track VERTEX PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS INC there?
VRTX earnings for the last quarter are 4.41 EUR per share, whereas the estimation was 3.77 EUR resulting in a 16.87% surprise. The estimated earnings for the next quarter are 3.86 EUR per share. See more details about VERTEX PHARMACEUTICALS INC earnings.
VERTEX PHARMACEUTICALS INC revenue for the last quarter amounts to 2.49 B EUR despite the estimated figure of 2.39 B EUR. In the next quarter revenue is expected to reach 2.47 B EUR.
Yes, you can track VERTEX PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
VRTX stock has risen by 4.83% compared to the previous week, the month change is a 4.80% rise, over the last year VERTEX PHARMACEUTICALS INC has showed a 21.89% increase.
VRTX net income for the last quarter is 1.02 B EUR, while the quarter before that showed 877.74 M EUR of net income which accounts for 16.10% change. Track more VERTEX PHARMACEUTICALS INC financial stats to get the full picture.
Today VERTEX PHARMACEUTICALS INC has the market capitalization of 101.19 B, it has increased by 0.85% over the last week.
No, VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
VRTX reached its all-time high on Jan 30, 2024 with the price of 416.85 EUR, and its all-time low was 104.50 EUR and was reached on May 24, 2017. View more price dynamics on VRTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 11, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS INC stock shows the buy signal. See more of VERTEX PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS INC future price: according to them, VRTX price has a max estimate of 535.17 EUR and a min estimate of 301.44 EUR. Watch VRTX chart and read a more detailed VERTEX PHARMACEUTICALS INC stock forecast: see what analysts think of VERTEX PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS INC EBITDA is 4.03 B EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICALS INC financial statements.